- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00020748
Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer
A Phase I Study of Epirubicin in Combination With Irinotecan in Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of epirubicin plus irinotecan in treating patients who have advanced cancer.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
- Determine the dose-limiting toxicity and maximum tolerated dose of epirubicin and irinotecan in patients with advanced cancer.
- Determine the objective antitumor responses in patients treated with this regimen.
- Determine the pharmacokinetics of this regimen in these patients.
OUTLINE: This is a dose-escalation study.
Patients receive irinotecan IV over 1 hour followed by epirubicin IV over 5 minutes on days 1 and 8. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Sequential dose escalation of epirubicin is followed by sequential dose escalation of irinotecan. Cohorts of 3-6 patients receive escalating doses of epirubicin and irinotecan until the maximum tolerated dose (MTD) of each is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for this study.
Studietyp
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
District of Columbia
-
Washington, District of Columbia, Förenta staterna, 20007
- Lombardi Cancer Center at Georgetown University Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Histologically documented incurable malignancy for which there is no beneficial standard therapy
- Locally unresectable or metastatic disease
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- At least 8 weeks
Hematopoietic:
- WBC at least 3,000/mm^3
- Granulocyte count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.2 times upper limit of normal (ULN)
- SGOT and SGPT no greater than 2 times ULN
Renal:
- Creatinine no greater than 1.5 mg/dL OR
- Creatinine clearance at least 60 mL/min
Cardiovascular:
- Ejection fraction at least 50% by MUGA scan
- No congestive heart failure
Other:
- Maintaining a reasonable state of nutrition
- No frequent vomiting or severe anorexia
- No weight loss greater than 10% of current body weight within the past 4 weeks
- No other concurrent medical illness that would preclude study
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No concurrent immunotherapy
Chemotherapy:
- Prior doxorubicin allowed if cumulative dose no greater than 240 mg/m2
Endocrine therapy:
- Not specified
Radiotherapy:
- No concurrent radiotherapy
Surgery:
- Not specified
Other:
- Recovered from prior therapy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: John L. Marshall, MD, Lombardi Comprehensive Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CDR0000068710
- P30CA051008 (U.S.S. NIH-anslag/kontrakt)
- GUMC-00191
- GUMC-072000-001
- NCI-G01-1956
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på irinotekanhydroklorid
-
Shanghai Zhangjiang Biotechnology Limited CompanyShanghai Biomabs Pharmaceutical Co., Ltd.AvslutadMetastaserande kolorektal cancer
-
M.D. Anderson Cancer CenterIndragenMetastaserande icke-småcelligt lungkarcinom | Steg IVA lungcancer AJCC v8 | Steg IVB lungcancer AJCC v8 | Steg IV lungcancer AJCC v8
-
Boston Scientific CorporationBiocompatibles UK LtdAvslutadMetastaserande kolorektal cancerStorbritannien, Österrike, Frankrike
-
Centre Oscar LambretSFCEAvslutad
-
New Mexico Cancer Care AllianceWyeth is now a wholly owned subsidiary of PfizerAvslutadSarkomFörenta staterna
-
Generic Devices Consulting, Inc.Biocompatibles UK LtdAvslutadInoperabel metastaserande tjock- och ändtarmscancerFörenta staterna
-
Uppsala UniversityRekryteringKolorektal cancer | Peritoneala metastaserSverige
-
H. Lee Moffitt Cancer Center and Research InstituteAvslutadGliom | Astrocytom | OligodendrogliomFörenta staterna
-
Enzon Pharmaceuticals, Inc.OkändMetastaserande kolorektal cancerFörenta staterna, Kanada, Israel, Nederländerna, Storbritannien
-
AbbVie (prior sponsor, Abbott)AvslutadFasta tumörerFörenta staterna